Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome

Haematologica

Volumn 94, Issue 5, 2009, Pages 602-606

  Della Porta, Matteo Giovanni ^a   Malcovati, Luca ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LEUKEMIA; AGING; ANEMIA; CANCER PATIENT; CAUSE OF DEATH; COMORBIDITY; EDITORIAL; HUMAN; MYELODYSPLASTIC SYNDROME; PROGNOSIS;

COMORBIDITY; GERMANY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LUNG DISEASES; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; STOMACH ULCER; SURVIVAL ANALYSIS;

EID: 66049088292     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.005702     Document Type: Editorial

References (20)

1. National Cancer Institute: Surveillance Epidemiology and End Results (SEER) registry. Bethesda, MD, National Cancer Institute. www.seer.cancer.gov.
2. Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002;20:494-502.
3. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. Jama 2004;291:2441-2447 (Pubitemid 38669187)
4. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud- Caspar I, Schäfer P, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003;21:3580-3587
5. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067 (Pubitemid 30035956)
6. Geraci JM, Escalante CP, Freeman JL, Goodwin JS. Comorbid disease and cancer: the need for more relevant conceptual models in health services research. J Clin Oncol 2005;23:7399-7404 (Pubitemid 46291800)
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383 (Pubitemid 17055592)
8. Piccirillo JF, Spitznagel EL Jr, Vermani N, Costas I, Schnitzler M. Comparison of comorbidity indices for patients with head and neck cancer. Med Care 2004;42:482-486
9. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-1261
10. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25: 1824-1831. (Pubitemid 46860271)
11. Cazzola M, Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005;352:536-558 (Pubitemid 40204666)
12. Germing U, Strupp C, Kündgen A, Bowen D, Aul C, Haas R, Gattermann N. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica 2004;89:905-910 (Pubitemid 39049897)
13. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007;92:1389-1398 (Pubitemid 350144157)
14. Zipperer E, Pelz D, Nachtkamp K, Kuendgen A, Strupp C, Gattermann N, et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009;94:xxx-xxx.
15. Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-7603
16. Kuendgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, Germing U. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006;24:5358-5365 (Pubitemid 46623166)
17. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006;91:1588-1590 (Pubitemid 46032954)
18. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-2919 (Pubitemid 41510773)
19. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007;25: 4246-4254
20. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002;87:1286-1306